argenx (NASDAQ:ARGX – Get Free Report) had its price objective upped by equities research analysts at Piper Sandler from $620.00 to $725.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s price target would indicate a potential upside of 12.34% from the company’s current price.
ARGX has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $617.00 price objective on shares of argenx in a research report on Wednesday, November 20th. Wells Fargo & Company boosted their price target on argenx from $639.00 to $723.00 and gave the stock an “overweight” rating in a research report on Thursday, December 19th. Truist Financial upped their price target on argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Finally, Scotiabank upgraded argenx from a “sector perform” rating to a “sector outperform” rating and upped their price target for the stock from $439.00 to $715.00 in a research note on Tuesday, November 5th. Three analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, argenx presently has a consensus rating of “Moderate Buy” and a consensus target price of $645.61.
Check Out Our Latest Analysis on argenx
argenx Trading Up 3.9 %
argenx (NASDAQ:ARGX – Get Free Report) last released its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same quarter last year, the firm earned ($1.25) earnings per share. As a group, sell-side analysts forecast that argenx will post 2.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On argenx
Large investors have recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd acquired a new position in argenx in the 2nd quarter valued at approximately $76,000. Cromwell Holdings LLC raised its holdings in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after acquiring an additional 66 shares in the last quarter. GAMMA Investing LLC raised its holdings in argenx by 47.5% in the 3rd quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after acquiring an additional 56 shares in the last quarter. Blue Trust Inc. raised its holdings in argenx by 413.9% in the 3rd quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after acquiring an additional 298 shares in the last quarter. Finally, Gallacher Capital Management LLC bought a new stake in shares of argenx in the 2nd quarter valued at approximately $202,000. Institutional investors and hedge funds own 60.32% of the company’s stock.
argenx Company Profile
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Read More
- Five stocks we like better than argenx
- Industrial Products Stocks Investing
- NVIDIA is Still the Most Important Stock in the Market
- Where to Find Earnings Call Transcripts
- 2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
- Ride Out The Recession With These Dividend Kings
- Will Berkshire Hathaway Continue to Dominate in 2025?
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.